A notice for Participants in the Add-Aspirin Breast Cohort

We were recently informed by the ABC breast cancer trial (A011502) team of a decision to stop their trial. Their oversight committee advised them that their trial was unlikely to show that aspirin would be better than placebo in preventing cancer returning. They reported no increase in side effects in patients receiving aspirin compared with those receiving placebo. The ABC trial team have advised that detailed results will be available in the first half of 2022.

Whilst the ABC trial was designed to answer a similar question to the one we are asking in Add-Aspirin, there are some important differences between the two trials. One difference is how long after being treated for breast cancer participants could join the trial. Add-Aspirin requires entry to the trial a few weeks after curative treatment for breast cancer. In the ABC trial participants could enter the trial up to 10 years after being treated for breast cancer. The ABC trial also allowed participants to enter who had previously been taking aspirin, provided they did not take it in the 30 days before starting the trial. In Add-Aspirin we do not allow regular prior aspirin use.

We provided all of this information to the Add-Aspirin oversight committee. They have advised that the Add-Aspirin trial should continue without any change. They will decide if they need to review their advice when further results from the ABC trial are available.

If you are a participant on the Add-Aspirin trial and have questions or concerns about this, please discuss them with your study nurse or doctor. You should continue to take your Add-Aspirin tablets and attend your scheduled follow-up visits.

The Add-Aspirin team would like to thank you for your continued participation in the Add-Aspirin study.

Contact Details

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For healthcare professionals

Please log into the members area for Add-Aspirin contact details.

Register Interest

For healthcare professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk

Register a participant

From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.

To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.

We have been experiencing intermittent issues with the trial websites. In the event of an emergency unblinding outside of office hours (including over the Easter bank holidays), if the usual unblinding links are not working, please telephone +(0)20 7670 4906 or +(0)20 7670 4892 to reach one of the Trial Managers.

Unblind a participant in the UK

Unblind a participant in the RoI

Unblind a participant in India